The gray-zone concept, suboptimal response to imatinib, shall be removed from the ELN-CML recommendations

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 20, Issue 2 SUPPL., 2010, Pages 25-26

  Haznedaroglu, Ibrahim C ^a   Koca, Ebru ^a   Aksu, Salih ^a   Goker, Hakan ^a   Sayinalp, Nilgun ^a   Buyukasik, Yahya ^a   Ozcebe, Osman I ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB; FUROSEMIDE; IDARUBICIN; IMATINIB; NILOTINIB;

BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG MEGADOSE; FACE EDEMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEG EDEMA; LETTER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 77955734957     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006.
2. Baccarani M, Cortes J, Pane F, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051, 2009.
3. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112: 4437-4444, 2008.
4. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu IC, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study. Blood 113: 4497-4504, 2009.
5. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113: 5401-5411, 2009.
6. Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107: 480-482, 2006.
7. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109: 3207-3213, 2007.
8. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22: 2176-2183, 2008.